Name | Title | Contact Details |
---|
Medico Mart Inc is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
In 1998, RPS began building the foundation for the PRO model in anticipation of evolving clinical strategies within Sponsor companies. By integrating its personnel and systems with those of Sponsor companies, RPS has helped industry leaders achieve significant cost savings, flexible program staffing, and standardized system operations on a global scale.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.
The National Quality Forum (NQF) is the nation`s resource for healthcare quality measurement and improvement. NQF is an independent, not-for-profit, membership-based organization that brings healthcare stakeholders together to recommend quality measures and improvement strategies that reduce costs and help patients get better care. NQF`s membership consists of more than 400 organizations that represent physicians, nurses, hospitals, healthcare systems, patients, families, health plans, employers, and others committed to healthcare quality. Through its multistakeholder membership, NQF facilitates an open and thorough dialogue on healthcare measurement and improvement, and leads national collaboration to improve health and healthcare quality for all Americans.
Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage. Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions. These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization. In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.